PORTFOLIO NEWS Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer August 24, 2021 Read More » NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research August 23, 2021 Read More » Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer August 17, 2021 Read More » RAPT Therapeutics Reports Second Quarter 2021 Financial Results August 11, 2021 Read More » Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress August 11, 2021 Read More » Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration August 11, 2021 Read More » ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update August 10, 2021 Read More » Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth August 5, 2021 Read More » NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results August 5, 2021 Read More » eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer August 4, 2021 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
Atavistik Bio Announces $60 Million Series A Financing to Advance Genetically-Validated Targets in Metabolic Diseases and Cancer August 24, 2021 Read More »
NGM Bio Discloses Fourth Oncology Development Candidate, NGM831, an ILT3 Antagonist Antibody, Coinciding with Publication in Cancer Immunology Research August 23, 2021 Read More »
Remix Therapeutics Names Peter Smith, PhD, as President and Chief Executive Officer August 17, 2021 Read More »
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress August 11, 2021 Read More »
Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration August 11, 2021 Read More »
ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update August 10, 2021 Read More »
Kallyope Announces CEO Transition as Company Advances to its Next Stage of Growth August 5, 2021 Read More »
NGM Bio Provides Business Highlights and Reports Second Quarter 2021 Financial Results August 5, 2021 Read More »
eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer August 4, 2021 Read More »
